<DOC>
	<DOCNO>NCT00448435</DOCNO>
	<brief_summary>To evaluate efficacy safety GW815SF HFA MDI 25/50µg 1 inhalation bid comparison concomitant treatment salmeterol xinafoate DPI 25µg 1 inhalation bid plus fluticasone propionate DPI 50µg 1 inhalation bid paediatric patient asthma . To evaluate safety long-term treatment GW815SF HFA MDI 25/50µg 1 inhalation bid paediatric patient asthma .</brief_summary>
	<brief_title>Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Inclusion criterion : Inclusion Criteria Entry Runin Period A pediatric patient already diagnose bronchial asthma meet follow criterion eligible study : Male female patient age ≥5 ≤14 year . Enrolment female patient childbearing potential allow test negative pregnancy test start Treatment Period 1 agrees undergo pregnancy test protocolspecified timing take contraceptive measure without fail . Written informed consent must obtain legally acceptable representative subject . Consent subject him/herself also obtain , wherever possible , give explanation easy understand possible manner . An outpatient treat ICS ( FP 100μg/day equivalent ) least 4 week prior Visit 1 . Able use peak flow meter correct manner investigator's/subinvestigator 's judgment . Able use MDI DPI correct manner ( assistance his/her caregiver necessary ) investigator's/subinvestigator 's judgment . Inclusion Criteria Entry Treatment Period 1 A subject randomize one two treatment group he/she complete runin period meet follow criterion . 1 . Has mean morning PEF measurement last 7 day runin period ( exclude first day Treatment Period 1 ) ≤90 % his/her best PEF measurement . 2 . Was able perform entry asthma diary PEF measurement correct manner investigator's/subinvestigator 's judgment . 3 . Able use MDI DPI correct manner ( assistance his/her caregiver necessary ) investigator's/subinvestigator 's judgment . Exclusion criterion : Exclusion Criteria Entry Runin Period A patient applies follow criterion eligible study : Admitted hospital due asthma exacerbation within 8 week prior Visit 1 . Used systemic steroid within 4 week prior Visit 1 . Received antibacterial antiviral treatment upper low respiratory tract infection within 2 week prior Visit 1 . Has safety problem participation study serious , uncontrolled systemic disease include nervous system disorder . Has suspect deepseated mycosis infection effective antibacterial agent available . Has suspect hypersensitivity investigational product , rescue medication ingredient . Is pregnant lactating , may pregnant , plan pregnancy study period . Has receive last dose another clinical study within 2 month prior study . Is eligible study investigator's/subinvestigator 's judgment . Exclusion Criteria Entry Treatment Period 1 Enrolment subject complete runin period Treatment Period 1 allow follow applies : 1 . Admitted hospital due asthma exacerbation runin period . 2 . Had upper low respiratory tract infection 2 week Visit 2 . 3 . Used prohibit drug 2 week Visit 2 . 4 . Is eligible study investigator's/subinvestigator 's judgment . Exclusion Criteria Entry Treatment Period 2 Enrolment subject complete washout period Treatment Period 2 allow follow applies : 1 . Admitted hospital due asthma exacerbation washout period . 2 . Had upper low respiratory tract infection 2 week Visit 4 . 3 . Used prohibit drug 2 week Visit 4 . 4 . Is eligible entry Treatment Period 2 investigator's/subinvestigator 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Salmeterol</keyword>
	<keyword>Fluticasone propionate</keyword>
	<keyword>Salmeterol/Fluticasone propionate combination</keyword>
	<keyword>Pediatric bronchial asthma</keyword>
</DOC>